ATX S10

Drug Profile

ATX S10

Latest Information Update: 26 Jan 2011

Price : $50

At a glance

  • Originator Photochemical Company
  • Class Antineoplastics
  • Mechanism of Action Photosensitisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Age-related macular degeneration; Cancer

Most Recent Events

  • 09 Oct 2003 ATX S10 is available for licensing
  • 16 Jun 2003 Bardeen Sciences has been acquired by Allergan
  • 31 Jan 2003 Allergan has terminated its licence for ATX S10
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top